Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond-Reference-Cited by-同舟云学术

Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond

Published:2016-02-10 Issue:1 Volume:270 Page:95-112
ISSN:0105-2896
Container-title:Immunological Reviews
language:en
Short-container-title:Immunol Rev

Author:

Donk Niels W. C. J.¹,Janmaat Maarten L.²,Mutis Tuna¹,Lammerts van Bueren Jeroen J.²,Ahmadi Tahamtan³,Sasser A. Kate³,Lokhorst Henk M.¹,Parren Paul W. H. I.²⁴⁵

Affiliation:

1. Department of Hematology VU University Medical Center Amsterdam the Netherlands

2. Genmab Utrecht the Netherlands

3. Janssen Research and Development Spring House PA USA

4. Department of Cancer and inflammation Research Institute of Molecular Medicine University of Southern Denmark Odense Denmark

5. Department of Immunohematology and Blood Transfusion Leiden University Medical Center Leiden the Netherlands

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imr.12389

Reference153 articles.

1. Discrete stages of human intrathymic differentiation: Analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage

2. Chromosome assignment of monoclonal antibody-defined determinants on human leukemic cells

3. Human CD38, a leukocyte receptor and ectoenzyme, is a member of a novel eukaryotic gene family of nicotinamide adenine dinucleotide+‐converting enzymes: extensive structural homology with the genes for murine bone marrow stromal cell antigen 1 and aplysian ADP‐ribosyl cyclase;Ferrero E;J Immunol,1997

4. Are follicular dendritic cells really good for nothing?

5. CD38 expression and functional activities are up-regulated by IFN-γ on human monocytes and monocytic cell lines

Cited by 268 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The surprising relationship between CD38 and lipid metabolic in acute myeloid leukemia;2024-01-24

2. Comprehensive analysis of thirteen-gene panel with prognosis value in Multiple Myeloma;Cancer Biomarkers;2023-12-15

3. Use of daratumumab drug formulation for subcutaneous administration in multiple myeloma therapy: Literature review and clinical observation;MD-Onco;2023-12-06

4. Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma;2023-12-04

5. Cancer drugs with high repositioning potential for Alzheimer’s disease;Expert Opinion on Emerging Drugs;2023-10-02